The latest study we are supporting is investigating if a new drug can preserve the beta cells in subjects diagnosed with type 1 diabetes.
The effect of anti-IL-21 and liraglutide in newly diagnosed type 1 diabetes
No longer recruiting
Summary
This study will investigate if a new drug called NNC01140006 (Anti-IL-21) when given together with another drug marketed for type 2 diabetes called liraglutide (Victoza®) can preserve the beta cells in subjects diagnosed with type 1 diabetes.
The study is for adults aged 18-45 years who have been diagnosed with type 1 diabetes within 20 weeks of the screening visit.
Recruiting site locations
Belfast, Birmingham, Blackburn, Bristol, Cardiff, Newcastle, London, Plymouth, Sheffield, Stevenage and Swansea
Read more about the trial on the NHS Health Research Authority website.
Read about other studies we are supporting.